TOKYO -- Japanese pharmaceutical group Eisai has essentially given up on a prospective blockbuster Alzheimer's disease drug and will instead focus resources on developing a follow-up offering.
Eisai had expected Aduhelm to generate more than 100 billion yen ($846 million) in annual revenue. The U.S. Food and Drug Administration granted conditional approval to the drug in June 2021.
